Beech Hill Advisors Inc. Purchases 50 Shares of Humana Inc. (NYSE:HUM)

Beech Hill Advisors Inc. grew its position in shares of Humana Inc. (NYSE:HUM) by 6.1% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 865 shares of the insurance provider’s stock after buying an additional 50 shares during the period. Beech Hill Advisors Inc.’s holdings in Humana were worth $229,000 at the end of the most recent quarter.

Other large investors have also recently added to or reduced their stakes in the company. Retirement Planning Co of New England Inc. increased its holdings in shares of Humana by 4.7% during the fourth quarter. Retirement Planning Co of New England Inc. now owns 966 shares of the insurance provider’s stock worth $245,000 after purchasing an additional 43 shares during the period. LFA Lugano Financial Advisors SA grew its position in Humana by 56.3% during the fourth quarter. LFA Lugano Financial Advisors SA now owns 125 shares of the insurance provider’s stock worth $32,000 after buying an additional 45 shares in the last quarter. First Horizon Advisors Inc. increased its stake in Humana by 11.5% during the 4th quarter. First Horizon Advisors Inc. now owns 581 shares of the insurance provider’s stock worth $148,000 after acquiring an additional 60 shares during the period. Oregon Public Employees Retirement Fund raised its holdings in Humana by 0.6% in the 4th quarter. Oregon Public Employees Retirement Fund now owns 10,316 shares of the insurance provider’s stock valued at $2,617,000 after acquiring an additional 62 shares in the last quarter. Finally, Vise Technologies Inc. lifted its position in shares of Humana by 8.0% during the 4th quarter. Vise Technologies Inc. now owns 873 shares of the insurance provider’s stock valued at $221,000 after acquiring an additional 65 shares during the period. Institutional investors own 92.38% of the company’s stock.

Humana Stock Down 0.0%

Shares of NYSE:HUM opened at $238.69 on Thursday. The firm has a market cap of $28.81 billion, a P/E ratio of 16.88, a P/E/G ratio of 1.80 and a beta of 0.43. Humana Inc. has a 12-month low of $212.45 and a 12-month high of $406.46. The business has a fifty day simple moving average of $242.88 and a 200 day simple moving average of $260.05. The company has a quick ratio of 1.91, a current ratio of 1.91 and a debt-to-equity ratio of 0.71.

Humana (NYSE:HUM) last posted its quarterly earnings data on Wednesday, April 30th. The insurance provider reported $11.58 EPS for the quarter, topping analysts’ consensus estimates of $10.07 by $1.51. Humana had a return on equity of 14.47% and a net margin of 1.42%. The company had revenue of $32.11 billion for the quarter, compared to analyst estimates of $32 billion. During the same period in the previous year, the firm earned $7.23 earnings per share. The firm’s quarterly revenue was up 8.4% on a year-over-year basis. Analysts predict that Humana Inc. will post 16.47 earnings per share for the current year.

Humana Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, July 25th. Investors of record on Friday, June 27th will be issued a $0.885 dividend. The ex-dividend date is Friday, June 27th. This represents a $3.54 annualized dividend and a yield of 1.48%. Humana’s payout ratio is 25.04%.

Analyst Upgrades and Downgrades

A number of research analysts recently commented on the company. Bank of America dropped their price target on Humana from $320.00 to $260.00 and set a “neutral” rating for the company in a research note on Tuesday, June 17th. Guggenheim started coverage on shares of Humana in a research report on Wednesday, April 9th. They issued a “buy” rating and a $326.00 target price for the company. Truist Financial set a $280.00 price target on shares of Humana and gave the stock a “hold” rating in a research report on Tuesday, June 17th. Barclays set a $268.00 price objective on shares of Humana and gave the company an “equal weight” rating in a research report on Thursday, June 12th. Finally, Raymond James Financial upgraded Humana from a “market perform” rating to an “outperform” rating and set a $315.00 price target on the stock in a research note on Thursday, May 1st. Seventeen research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. According to MarketBeat, the company currently has an average rating of “Hold” and an average target price of $280.76.

Humana Company Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.